LakeShore Biopharma Co., Ltd (LSB)

Market Cap	55.33M
Revenue (ttm)	79.42M
Net Income (ttm)	-60.03M
Shares Out	19.08M
EPS (ttm)	-5.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,885
Open	3.210
Previous Close	3.120
Day's Range	2.700 - 3.250
52-Week Range	2.700 - 11.200
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About LSB

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 758
• Stock Exchange: NASDAQ
• Ticker Symbol: LSB
• Website: https://www.ysbiopharm.com

Financial Performance

In 2023, LakeShore Biopharma's revenue was 573.42 million, a decrease of -16.56% compared to the previous year's 687.20 million. Losses were -433.46 million, 198.0% more than in 2022.

Financial numbers in CNY